Drugs / Anti-CD19-CAR transduced T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02456350 | Apr 2015 → Dec 2019 | B-cell chronic lymphocytic leukemia | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03191773 | Jun 2017 → Dec 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Second Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03076437 | Jan 2016 → May 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Shenzhen Institute for Innovation and Translational Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 CAR-transduced T cells | “The patients will be pretreated with a lymphodepleting preconditioning regimen before the infusion of anti-CD19 CAR T cells, and will be monitored for adverse events,...” NCT02456350 ↗3“Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.” NCT03191773 ↗ |
| Known as | anti-CD19 CAR T cells | “The patients will be pretreated with a lymphodepleting preconditioning regimen before the infusion of anti-CD19 CAR T cells, and will be monitored for adverse events,...” NCT02456350 ↗ |
| Modality | Cell therapy | “autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR)” NCT02456350 ↗ |
| Route | Intravenous | “Modified cells will be infused IV over 30 minutes” NCT02456350 ↗ |
| Target | CD19 | “anti-CD19 chimeric antigen receptor (CAR)” NCT02456350 ↗ |